Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Eric S. Winer, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Clinical Director, Adult Leukemia
  • Senior Physician
  • Assistant Professor of Medicine, Harvard Medical School

Centers/Programs

Diseases Treated

Contact Information

  • Appointments617-632-6028 (new)
    617-632-1906 (follow-up)
  • Office Phone Number617-632-1906
  • Fax617-632-5175

Bio

Dr. Winer received his MD from The University of North Carolina School of Medicine in 1999. He completed his residency in Internal Medicine at Tufts Medical Center. He remained at Tufts Medical Center for a clinical hematology/oncology fellowship, which he completed in 2005.

Board Certification:

  • Hematology, 2006
  • Internal Medicine, 2002
  • Medical Oncology, 2005

Fellowship:

  • Tufts Medical Center, Hematology/Oncology

Residency:

  • Tufts Medical Center, Internal Medicine

Medical School:

  • University of North Carolina School of Medicine

Research

Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Apr 24.
View in: PubMed

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer. JCI Insight. 2021 Apr 22.
View in: PubMed

Impact of cancer history on outcomes among hospitalized COVID-19 patients. Oncologist. 2021 Apr 15.
View in: PubMed

Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. J Natl Cancer Inst. 2021 Apr 06; 113(4):443-452.
View in: PubMed

Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. J Natl Cancer Inst. 2021 04 06; 113(4):355-359.
View in: PubMed

Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. JAMA Oncol. 2021 Apr 01; 7(4):609-615.
View in: PubMed

A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. Int J Radiat Oncol Biol Phys. 2021 Mar 10.
View in: PubMed

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 04; 22(4):499-511.
View in: PubMed

Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Feb 16.
View in: PubMed

Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2021 May; 87(5):673-679.
View in: PubMed

Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer. Oncology (Williston Park). 2021 Feb 11; 35(2):77-84.
View in: PubMed

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021 Feb 01.
View in: PubMed

The global landscape of treatment standards for breast cancer. J Natl Cancer Inst. 2021 Jan 27.
View in: PubMed

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021 02; 22(2):212-222.
View in: PubMed

Perceptions of patients with early stage breast cancer toward research biopsies. Cancer. 2021 Apr 15; 127(8):1208-1219.
View in: PubMed

Genomic Characterization of de novo Metastatic Breast Cancer. Clin Cancer Res. 2021 Feb 15; 27(4):1105-1118.
View in: PubMed

Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2021 Feb 15; 27(4):983-991.
View in: PubMed

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res. 2020 11 30; 22(1):131.
View in: PubMed

Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2021 Feb; 186(1):157-165.
View in: PubMed

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2020 11 02; 22(1):120.
View in: PubMed

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 12 20; 38(36):4274-4282.
View in: PubMed

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 12 10; 38(35):4184-4193.
View in: PubMed

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1598-1605.
View in: PubMed

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020 Dec 01; 26(23):6149-6157.
View in: PubMed

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020 12; 31(12):1623-1649.
View in: PubMed

Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2021 Jan; 185(1):215-227.
View in: PubMed

A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials. Ann Oncol. 2020 12; 31(12):1704-1708.
View in: PubMed

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Ann Oncol. 2020 11; 31(11):1518-1525.
View in: PubMed

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clin Cancer Res. 2020 Nov 15; 26(22):5974-5989.
View in: PubMed

Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Clin Cancer Res. 2020 Sep 15; 26(18):4911-4920.
View in: PubMed

Therapy for HER2-Positive Metastatic Breast Cancer. Reply. N Engl J Med. 2020 06 18; 382(25):e98.
View in: PubMed

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020 08 10; 38(23):2610-2619.
View in: PubMed

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Ann Oncol. 2020 09; 31(9):1231-1239.
View in: PubMed

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discov. 2020 Aug; 10(8):1174-1193.
View in: PubMed

Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. Clin Breast Cancer. 2020 10; 20(5):395-401.e3.
View in: PubMed

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.
View in: PubMed

Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564.
View in: PubMed

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020 05 10; 38(14):1539-1548.
View in: PubMed

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020 05; 31(5):582-589.
View in: PubMed

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol. 2020 05; 31(5):590-598.
View in: PubMed

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2565-2572.
View in: PubMed

A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):238-245.
View in: PubMed

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. J Cell Mol Med. 2020 02; 24(3):2145-2156.
View in: PubMed

Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 2020 03; 31(3):387-394.
View in: PubMed

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 02 13; 382(7):597-609.
View in: PubMed

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. J Clin Oncol. 2020 03 01; 38(7):725-733.
View in: PubMed

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):44-59.
View in: PubMed

Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
View in: PubMed

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2019 11 01; 30(11):1842.
View in: PubMed

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 10 01; 30(10):1541-1557.
View in: PubMed

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123.
View in: PubMed

Reply to A.K. Goel et al. J Clin Oncol. 2019 11 01; 37(31):2954-2955.
View in: PubMed

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520.
View in: PubMed

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2.
View in: PubMed

Aggressive Subsets of Metastatic Triple Negative Breast Cancer. Clin Breast Cancer. 2020 02; 20(1):e20-e26.
View in: PubMed

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
View in: PubMed

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
View in: PubMed

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019 08; 117:91-98.
View in: PubMed

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer. 2019 12; 19(6):399-404.
View in: PubMed

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. Clin Cancer Res. 2019 08 01; 25(15):4644-4655.
View in: PubMed

Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study. Clin Cancer Res. 2019 Sep 01; 25(17):5398-5406.
View in: PubMed

Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310.
View in: PubMed

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875.
View in: PubMed

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Ann Oncol. 2019 04 01; 30(4):575-581.
View in: PubMed

Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580.
View in: PubMed

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089.
View in: PubMed

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019 03 01; 30(3):397-404.
View in: PubMed

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019 03 01; 30(3):405-411.
View in: PubMed

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clin Cancer Res. 2019 05 15; 25(10):2975-2987.
View in: PubMed

TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol. 2019 03 20; 37(9):714-722.
View in: PubMed

Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study. Ann Oncol. 2019 01 01; 30(1):13-16.
View in: PubMed

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat Genet. 2019 02; 51(2):207-216.
View in: PubMed

Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. Oncologist. 2019 07; 24(7):e441-e449.
View in: PubMed

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019 02 10; 37(5):423-438.
View in: PubMed

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 11 29; 379(22):2108-2121.
View in: PubMed

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018 Oct 01; 29(10):2153.
View in: PubMed

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer. 2018; 4:22.
View in: PubMed

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018 08 01; 29(8):1634-1657.
View in: PubMed

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res. 2018 11 01; 24(21):5292-5304.
View in: PubMed

CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018; 10:1758835918786451.
View in: PubMed

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018 07 01; 29(7):1541-1547.
View in: PubMed

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018 09 20; 36(27):2804-2807.
View in: PubMed

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018 09 10; 36(26):2736-2740.
View in: PubMed

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
View in: PubMed

Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Res Treat. 2018 Aug; 171(1):21-31.
View in: PubMed

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018; 4:10.
View in: PubMed

Predicting breast cancer therapeutic response. Nat Med. 2018 05; 24(5):535-537.
View in: PubMed

Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway. J Natl Cancer Inst. 2018 05 01; 110(5):443-445.
View in: PubMed

Breast cancer-specific survival by age: Worse outcomes for the oldest patients. Cancer. 2018 05 15; 124(10):2184-2191.
View in: PubMed

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell. 2018 02 12; 33(2):173-186.e5.
View in: PubMed

Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res. 2018 04 15; 24(8):1795-1804.
View in: PubMed

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018 03 20; 36(9):884-890.
View in: PubMed

Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018 Apr; 168(3):727-737.
View in: PubMed

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018 02 20; 36(6):543-553.
View in: PubMed

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. Ann Oncol. 2018 01 01; 29(1):281-282.
View in: PubMed

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017 12 01; 28(12):3111.
View in: PubMed

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. NPJ Breast Cancer. 2017; 3:37.
View in: PubMed

CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 08 24; 548(7668):471-475.
View in: PubMed

Breast cancer: T-DM1 - an important agent in the history of breast cancer management. Nat Rev Clin Oncol. 2017 11; 14(11):651-652.
View in: PubMed

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 08 01; 28(8):1700-1712.
View in: PubMed

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5687-5695.
View in: PubMed

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J. 2017 09; 19(5):1411-1423.
View in: PubMed

Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy? J Natl Cancer Inst. 2017 Apr 01; 109(4).
View in: PubMed

Reply to S. Sorscher. J Clin Oncol. 2017 05 20; 35(15):1746-1747.
View in: PubMed

Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. J Natl Compr Canc Netw. 2017 03; 15(3):316-324.
View in: PubMed

Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review. JAMA Oncol. 2017 Mar 01; 3(3):402-409.
View in: PubMed

Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study. Oncologist. 2017 04; 22(4):386-393.
View in: PubMed

Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. Breast. 2017 04; 32:269-270.
View in: PubMed

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative). J Am Coll Surg. 2017 Apr; 224(4):688-694.
View in: PubMed

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017 Apr 01; 35(10):1061-1069.
View in: PubMed

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017 01 01; 28(1):16-33.
View in: PubMed

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. J Clin Oncol. 2017 Feb; 35(4):421-431.
View in: PubMed

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017 Feb; 31:244-259.
View in: PubMed

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat. 2017 01; 161(2):363-373.
View in: PubMed

Perils of the Pathologic Complete Response. J Clin Oncol. 2016 11 20; 34(33):3959-3962.
View in: PubMed

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist. 2017 01; 22(1):25-32.
View in: PubMed

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016 11 03; 375(18):1738-1748.
View in: PubMed

Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast. 2016 Dec; 30:136-140.
View in: PubMed

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Res Treat. 2016 11; 160(2):305-312.
View in: PubMed

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 11; 160(2):297-304.
View in: PubMed

Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62.
View in: PubMed

Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. J Clin Oncol. 2016 09 20; 34(27):3308-14.
View in: PubMed

I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment. N Engl J Med. 2016 Jul 07; 375(1):83-4.
View in: PubMed

The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. Clin Cancer Res. 2016 Dec 15; 22(24):6039-6050.
View in: PubMed

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 07; 22(7):723-6.
View in: PubMed

Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Res Treat. 2016 06; 157(3):587-96.
View in: PubMed

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med. 2016 Jul 21; 375(3):209-19.
View in: PubMed

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Jun; 17(6):811-821.
View in: PubMed

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 08 01; 34(22):2602-9.
View in: PubMed

A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Jan 01; 23(1):26-34.
View in: PubMed

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016 May 01; 34(13):1460-8.
View in: PubMed

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016 Mar 14; 29(3):255-269.
View in: PubMed

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016 08 01; 22(15):3764-73.
View in: PubMed

Timeliness in Breast Cancer Treatment-The Sooner, the Better. JAMA Oncol. 2016 Mar; 2(3):302-4.
View in: PubMed

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016 05 10; 34(14):1689-701.
View in: PubMed

Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer. 2016 Apr 15; 122(8):1169-77.
View in: PubMed

Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78.
View in: PubMed

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. Clin Cancer Res. 2016 07 01; 22(13):3249-59.
View in: PubMed

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52.
View in: PubMed

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016 Jan 21; 529(7586):413-417.
View in: PubMed

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36.
View in: PubMed

Response. J Natl Cancer Inst. 2016 Jan; 108(1).
View in: PubMed

PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 06 09; 35(23):2961-70.
View in: PubMed

Response. J Natl Cancer Inst. 2015 Jan; 108(1).
View in: PubMed

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol. 2016 Feb 20; 34(6):542-9.
View in: PubMed

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A. 2015 Nov 17; 112(46):14325-30.
View in: PubMed

POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer. Oncology (Williston Park). 2015 Nov; 29(11):797-8, 802.
View in: PubMed

PI3K-p110a mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene. 2016 07 07; 35(27):3607-12.
View in: PubMed

Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat. 2015 Nov; 154(2):359-67.
View in: PubMed

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
View in: PubMed

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg. 2015 Sep; 262(3):434-9; discussion 438-9.
View in: PubMed

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. Breast. 2015 Nov; 24 Suppl 2:S132-5.
View in: PubMed

Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. Oncologist. 2015 Sep; 20(9):992-1000.
View in: PubMed

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. J Clin Oncol. 2015 Sep 01; 33(25):2772-9.
View in: PubMed

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
View in: PubMed

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol. 2015 Aug 20; 33(24):2623-31.
View in: PubMed

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs. 2015 Oct; 33(5):1108-14.
View in: PubMed

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst. 2015 Sep; 107(9).
View in: PubMed

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015 Jul 20; 33(21):2361-9.
View in: PubMed

Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. Oncologist. 2015 Jul; 20(7):713-8.
View in: PubMed

Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat. 2015 Jun; 151(3):697-707.
View in: PubMed

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96.
View in: PubMed

Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. J Clin Oncol. 2015 Jul 10; 33(20):2254-61.
View in: PubMed

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug; 26(8):1533-46.
View in: PubMed

Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. Ann Surg Oncol. 2015 Nov; 22(12):3809-15.
View in: PubMed

Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Ann Surg Oncol. 2015 Dec; 22(13):4280-6.
View in: PubMed

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015 Jun 10; 33(17):1902-9.
View in: PubMed

Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48.
View in: PubMed

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
View in: PubMed

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol. 2015 Mar 01; 33(7):701-8.
View in: PubMed

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41.
View in: PubMed

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer. J Clin Oncol. 2015 Mar 20; 33(9):969-71.
View in: PubMed

Personalization of loco-regional care for primary breast cancer patients (part 1). Future Oncol. 2015; 11(9):1297-300.
View in: PubMed

Personalization of loco-regional care for primary breast cancer patients (part 2). Future Oncol. 2015; 11(9):1301-5.
View in: PubMed

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):151-61.
View in: PubMed

Reply to V. Amoroso et al. J Clin Oncol. 2015 Jan 20; 33(3):291.
View in: PubMed

Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46.
View in: PubMed

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014 Dec 10; 32(35):3959-66.
View in: PubMed

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2014 Dec 01; 32(34):3840-7.
View in: PubMed

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20; 32(33):3744-52.
View in: PubMed

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014 Oct; 23(5):489-502.
View in: PubMed

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol. 2014 Oct; 25(10):1871-1888.
View in: PubMed

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14.
View in: PubMed

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014 Nov; 25(11):2211-2217.
View in: PubMed

Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30.
View in: PubMed

Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer. 2014 Oct 14; 111(8):1532-41.
View in: PubMed

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 01; 33(1):13-21.
View in: PubMed

Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). J Oncol Pract. 2014 Sep; 10(5):e285-92.
View in: PubMed

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014 Aug; 146(3):557-66.
View in: PubMed

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 01; 32(22):2311-7.
View in: PubMed

Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. J Clin Oncol. 2014 Aug 01; 32(22):2318-27.
View in: PubMed

Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. J Cancer Surviv. 2014 Dec; 8(4):627-37.
View in: PubMed

Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. Clin Breast Cancer. 2014 Dec; 14(6):413-6.
View in: PubMed

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014 Nov 01; 32(31):3483-9.
View in: PubMed

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50.
View in: PubMed

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18.
View in: PubMed

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014 Jul 20; 32(21):2255-69.
View in: PubMed

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014 Aug; 25(8):1656-63.
View in: PubMed

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jul 01; 32(19):2078-99.
View in: PubMed

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jul 01; 32(19):2100-8.
View in: PubMed

Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat. 2014 Jun; 145(2):491-501.
View in: PubMed

Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. Leukemia. 2014 Nov; 28(11):2165-77.
View in: PubMed

Male breast cancer networking and telephone support group: a model for supporting a unique population. Psychooncology. 2014 Aug; 23(8):956-8.
View in: PubMed

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2014 Apr 20; 32(12):1202-9.
View in: PubMed

Defining success in neoadjuvant breast cancer trials. Lancet. 2014 Jul 12; 384(9938):115-6.
View in: PubMed

Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharmacogenomics J. 2014 Aug; 14(4):336-42.
View in: PubMed

Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014 Mar 20; 32(9):927-34.
View in: PubMed

A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Med. 2014 Apr; 3(2):293-9.
View in: PubMed

Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan; 12(1):71-80.
View in: PubMed

Breast cancer presentation and diagnostic delays in young women. Cancer. 2014 Jan 01; 120(1):20-5.
View in: PubMed

A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14.
View in: PubMed

Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al. J Clin Oncol. 2013 Dec 20; 31(36):4571-3.
View in: PubMed

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clin Cancer Res. 2014 Jan 01; 20(1):15-20.
View in: PubMed

Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013 Nov; 142(1):203-9.
View in: PubMed

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7.
View in: PubMed

Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 2013 Sep 17; 159(6):373-81.
View in: PubMed

Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction. Breast Cancer Res Treat. 2013 Sep; 141(2):255-9.
View in: PubMed

Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer. 2013 Nov 15; 119(22):3943-51.
View in: PubMed

Pertuzumab: optimizing HER2 blockade. Clin Cancer Res. 2013 Oct 15; 19(20):5552-6.
View in: PubMed

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep; 24(9):2206-23.
View in: PubMed

Q&A: Eric Winer on neoadjuvant clinical trials. Cancer Discov. 2013 Aug; 3(8):832.
View in: PubMed

Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. 2013 Aug; 13(4):254-63.
View in: PubMed

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Res Treat. 2013 Jul; 140(2):331-9.
View in: PubMed

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
View in: PubMed

A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901. J Geriatr Oncol. 2013 Oct; 4(4):353-61.
View in: PubMed

Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol. 2013 Jul 20; 31(21):2692-8.
View in: PubMed

Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 01; 31(19):2382-7.
View in: PubMed

Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat. 2013 Jun; 139(2):607-16.
View in: PubMed

Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Serv Res. 2013 Oct; 48(5):1669-83.
View in: PubMed

A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10.
View in: PubMed

International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013 Jun; 22(3):203-10.
View in: PubMed

Long-term risk perceptions of women with ductal carcinoma in situ. Oncologist. 2013; 18(4):362-8.
View in: PubMed

A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol. 2013 Jul; 24(7):1841-1847.
View in: PubMed

Attitudes of patients with metastatic breast cancer toward research biopsies. Ann Oncol. 2013 Jul; 24(7):1853-1859.
View in: PubMed

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):457-66.
View in: PubMed

Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol. 2013 Jun; 24(6):1434-43.
View in: PubMed

High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13.
View in: PubMed

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013 Aug; 22(4):525-31.
View in: PubMed

Quality of life and symptoms in male breast cancer survivors. Breast. 2013 Apr; 22(2):197-199.
View in: PubMed

Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9.
View in: PubMed

Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Res Treat. 2012 Dec; 136(3):919-26.
View in: PubMed

Body image in recently diagnosed young women with early breast cancer. Psychooncology. 2013 Aug; 22(8):1849-55.
View in: PubMed

Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat. 2012 Dec; 136(3):813-21.
View in: PubMed

Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol. 2013 Feb; 24(2):283-291.
View in: PubMed

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov; 136(1):169-78.
View in: PubMed

Survival implications associated with variation in mastectomy rates for early-staged breast cancer. Int J Surg Oncol. 2012; 2012:127854.
View in: PubMed

The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012 Aug; 26(8):688-94, 696.
View in: PubMed

Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice? J Clin Oncol. 2012 Sep 01; 30(25):3148-9; author reply 3149-50.
View in: PubMed

A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep 15; 18(18):5099-109.
View in: PubMed

Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis. Cancer. 2013 Jan 15; 119(2):250-8.
View in: PubMed

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20; 30(33):4071-6.
View in: PubMed

Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ. J Sex Med. 2013 Feb; 10(2):370-7.
View in: PubMed

Aromatase inhibition in obese women: how much is enough? J Clin Oncol. 2012 Aug 20; 30(24):2940-2.
View in: PubMed

Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat. 2012 Aug; 134(3):1305-13.
View in: PubMed

Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol. 2012 Dec; 23(12):3075-3081.
View in: PubMed

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20; 30(21):2615-23.
View in: PubMed

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012 Sep 10; 30(26):3234-41.
View in: PubMed

Model program to improve care for a unique cancer population: young women with breast cancer. J Oncol Pract. 2012 Sep; 8(5):e105-10.
View in: PubMed

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012 Jun 20; 30(18):2179-82.
View in: PubMed

The effect of age on delay in diagnosis and stage of breast cancer. Oncologist. 2012; 17(6):775-82.
View in: PubMed

Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012 Nov 15; 118(22):5463-72.
View in: PubMed

Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer. 2012 Apr; 12(2):119-26.
View in: PubMed

1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012 Jun; 21(3):242-52.
View in: PubMed

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012 Jun; 133(3):1057-65.
View in: PubMed

The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. J Clin Oncol. 2012 Mar 01; 30(7):690-1.
View in: PubMed

Further progress in HER2-directed therapy. Lancet Oncol. 2012 Jan; 13(1):2-3.
View in: PubMed

A dickens tale of the treatment of advanced breast cancer: the past, the present, and the future. Am Soc Clin Oncol Educ Book. 2012; 28-38.
View in: PubMed

Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol. 2012 Jan 10; 30(2):158-63.
View in: PubMed

Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012 Feb; 131(3):1061-6.
View in: PubMed

Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J. 2012 Jan-Feb; 18(1):23-7.
View in: PubMed

Adjuvant chemotherapy in luminal breast cancers. Breast. 2011 Oct; 20 Suppl 3:S128-31.
View in: PubMed

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist. 2011; 16(10):1359-66.
View in: PubMed

Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Res Treat. 2012 Jan; 131(2):589-97.
View in: PubMed

Should a sentinel node biopsy be performed in patients with high-risk breast cancer? Int J Breast Cancer. 2011; 2011:973245.
View in: PubMed

The ethical use of mandatory research biopsies. Nat Rev Clin Oncol. 2011 08 02; 8(10):620-5.
View in: PubMed

American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol. 2011 Oct 01; 29(28):3816-24.
View in: PubMed

Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1075-80.
View in: PubMed

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011 Aug 10; 29(23):3126-32.
View in: PubMed

CMF revisited in the 21st century. Ann Oncol. 2012 Feb; 23(2):305-11.
View in: PubMed

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol. 2011 Dec; 105(3):613-20.
View in: PubMed

A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer. 2011 Dec; 11(6):376-83.
View in: PubMed

p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 01; 17(15):5170-8.
View in: PubMed

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol. 2012 Mar; 23(3):632-638.
View in: PubMed

Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97.
View in: PubMed

Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference. Ann Surg Oncol. 2011 Oct; 18(10):2885-92.
View in: PubMed

GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Res. 2011 Jul; 39(12):4928-41.
View in: PubMed

Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011 May 15; 17(10):3490-9.
View in: PubMed

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9.
View in: PubMed

Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. J Clin Oncol. 2011 Mar 10; 29(8):1022-8.
View in: PubMed

Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight. J Clin Oncol. 2011 Jan 20; 29(3):251-3.
View in: PubMed

The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011 Jan 01; 117(1):180-9.
View in: PubMed

Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw. 2010 Oct; 8(10):1182-207.
View in: PubMed

Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol. 2011 Mar; 18(3):733-7.
View in: PubMed

Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010 Dec; 7(12):683-92.
View in: PubMed

Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res. 2010 Oct 01; 16(19):4702-10.
View in: PubMed

Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010 Sep-Oct; 17(5):908-16.
View in: PubMed

Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010 Sep-Oct; 53(2):94-104.
View in: PubMed

Physical and psychological outcomes among women in a telephone-based exercise intervention during adjuvant therapy for early stage breast cancer. J Womens Health (Larchmt). 2010 Aug; 19(8):1553-9.
View in: PubMed

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010 Aug 10; 28(23):3784-96.
View in: PubMed

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010 Jul 07; 102(13):942-9.
View in: PubMed

Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol. 2010 Jul 01; 28(19):3146-53.
View in: PubMed

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol. 2010 Jun 20; 28(18):2982-8.
View in: PubMed

Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Res Treat. 2011 Feb; 125(3):803-13.
View in: PubMed

Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol. 2010 May 10; 28(14):2418-22.
View in: PubMed

International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst. 2010 Apr 07; 102(7):456-63.
View in: PubMed

The role of socioeconomic status in adjustment after ductal carcinoma in situ. Cancer. 2010 Mar 01; 116(5):1218-25.
View in: PubMed

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010 Mar 01; 28(7):1145-53.
View in: PubMed

Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. Breast. 2010 Apr; 19(2):69-75.
View in: PubMed

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65.
View in: PubMed

Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women. Breast Cancer Res Treat. 2010 Jun; 121(3):743-51.
View in: PubMed

On mammography--more agreement than disagreement. N Engl J Med. 2009 Dec 24; 361(26):2499-501.
View in: PubMed

Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23.
View in: PubMed

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Dec 10; 27(35):6052-69.
View in: PubMed

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 2009 Dec 01; 27(34):5671-3.
View in: PubMed

Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009 Oct; 133(10):1515-38.
View in: PubMed

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst. 2009 Sep 02; 101(17):1174-81.
View in: PubMed

Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery? Med Care. 2009 Jul; 47(7):765-73.
View in: PubMed

Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol. 2009 Jul 20; 27(21):3430-6.
View in: PubMed

Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65.
View in: PubMed

Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors. Cancer Causes Control. 2009 Oct; 20(8):1523-8.
View in: PubMed

Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009 May; 9(2):101-7.
View in: PubMed

Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 Oct; 117(3):615-23.
View in: PubMed

ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol. 2009 Feb 27; 2:11.
View in: PubMed

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009 Feb 15; 15(4):1452-9.
View in: PubMed

Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92.
View in: PubMed

A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer. 2009 Feb; 9(1):39-44.
View in: PubMed

Sharing study results with trial participants: time for action. J Clin Oncol. 2009 Feb 20; 27(6):838-9.
View in: PubMed

Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009 Jan; 133(1):15-25.
View in: PubMed

Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol. 2009 Feb 10; 27(5):713-9.
View in: PubMed

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26.
View in: PubMed

Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008 Dec 15; 14(24):8010-8.
View in: PubMed

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7.
View in: PubMed

Reducing disparities in breast cancer care: a daunting but essential responsibility. J Natl Cancer Inst. 2008 Dec 03; 100(23):1661-3.
View in: PubMed

Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008 Dec 20; 26(36):5994-6000.
View in: PubMed

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008 Nov 15; 113(10):2638-45.
View in: PubMed

Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology. 2008 Nov; 17(11):1108-20.
View in: PubMed

Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ. Ann Surg Oncol. 2009 Jan; 16(1):106-12.
View in: PubMed

Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer. 2008 Aug; 8(4):352-6.
View in: PubMed

The optimal duration of adjuvant hormonal therapy for early-stage breast cancer. Clin Adv Hematol Oncol. 2008 Aug; 6(8):573-4.
View in: PubMed

Newer monoclonal antibodies for hematological malignancies. Exp Hematol. 2008 Jul; 36(7):755-68.
View in: PubMed

Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009 May; 115(1):7-12.
View in: PubMed

The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat. 2009 May; 115(1):123-9.
View in: PubMed

Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. J Clin Oncol. 2008 Jun 01; 26(16):2659-65.
View in: PubMed

Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ. Clin Breast Cancer. 2008 Jun; 8(3):275-80.
View in: PubMed

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May; 115(1):115-21.
View in: PubMed

Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Res Treat. 2009 Jan; 113(2):207-9.
View in: PubMed

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008 May 07; 100(9):642-8.
View in: PubMed

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
View in: PubMed

Tangential radiotherapy without axillary surgery in early-stage breast cancer: results of a prospective trial. Int J Radiat Oncol Biol Phys. 2008 Nov 01; 72(3):866-70.
View in: PubMed

Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 01; 26(10):1642-9.
View in: PubMed

Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time. J Clin Oncol. 2008 Apr 20; 26(12):1919-21.
View in: PubMed

Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health. 2008 Mar-Apr; 11(2):213-20.
View in: PubMed

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009 Feb; 113(3):479-90.
View in: PubMed

Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol. 2008 Feb 20; 26(6):907-12.
View in: PubMed

Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst. 2008 Feb 20; 100(4):243-51.
View in: PubMed

Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008 Feb 10; 26(5):798-805.
View in: PubMed

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9.
View in: PubMed

Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol. 2008 Feb 10; 26(5):696-7.
View in: PubMed

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008 Mar 10; 26(8):1231-8.
View in: PubMed

Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer. 2008 Feb 01; 112(3 Suppl):700-709.
View in: PubMed

Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008 Feb 01; 112(3 Suppl):673-678.
View in: PubMed

Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer. 2008 Feb; 8(1):65-9.
View in: PubMed

Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30.
View in: PubMed

Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008 Feb 01; 26(4):556-62.
View in: PubMed

NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008; 6 Suppl 4:S1-25; quiz S26-7.
View in: PubMed

Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer. 2008; 15(1):31-4.
View in: PubMed

Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25.
View in: PubMed

Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol. 2007 Nov 01; 96(6):474-80.
View in: PubMed

Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. Radiology. 2007 Dec; 245(3):824-30.
View in: PubMed

Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer. N Engl J Med. 2007 Oct 18; 357(16):1640-8.
View in: PubMed

Care in the months before death and hospice enrollment among older women with advanced breast cancer. J Gen Intern Med. 2008 Jan; 23(1):11-8.
View in: PubMed

HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506.
View in: PubMed

Sarcoidosis mimicking metastatic breast cancer. Clin Breast Cancer. 2007 Oct; 7(10):804-10.
View in: PubMed

Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 Oct; 16(10):895-903.
View in: PubMed

Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health. 2007 Sep-Oct; 10(5):367-76.
View in: PubMed

Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007 Sep 01; 25(25):3797-9.
View in: PubMed

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 01; 110(5):965-72.
View in: PubMed

Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007 Aug 20; 25(24):3699-704.
View in: PubMed

Follow-up care of patients with breast cancer. Breast. 2007 Dec; 16 Suppl 2:S45-50.
View in: PubMed

Optimal use of aromatase inhibitors: to lead or to follow? J Clin Oncol. 2007 Jul 01; 25(19):2639-41.
View in: PubMed

Local therapy and survival in breast cancer. N Engl J Med. 2007 Jun 07; 356(23):2399-405.
View in: PubMed

Cryopreservation of hematopoietic stem cells. Am J Hematol. 2007 Jun; 82(6):463-72.
View in: PubMed

Erratum: Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 May 24; 16(10).
View in: PubMed

Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007 Jul; 43(11):1646-53.
View in: PubMed

Implementing an interdisciplinary governance model in a comprehensive cancer center. Oncol Nurs Forum. 2007 May; 34(3):611-6.
View in: PubMed

Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer. 2007 Apr 01; 109(7):1239-46.
View in: PubMed

Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol. 2007 Mar 20; 25(9):1074-81.
View in: PubMed

Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007 Mar 15; 13(6):1648-55.
View in: PubMed

Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.
View in: PubMed

Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar; 5(3):246-312.
View in: PubMed

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207.
View in: PubMed

Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations. J Cancer Educ. 2007; 22(1):21-4.
View in: PubMed

Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5330-1.
View in: PubMed

Virtual Reality Exposure Therapy for PTSD symptoms after a road accident: an uncontrolled case series. Behav Ther. 2007 Mar; 38(1):39-48.
View in: PubMed

Menopausal-type symptoms in young breast cancer survivors. Ann Oncol. 2006 Dec; 17(12):1777-82.
View in: PubMed

Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs. 2007 Apr; 25(2):161-4.
View in: PubMed

Cancer-related communication between female patients and male partners scale: A pilot study. Psychooncology. 2006 Sep; 15(9):780-94.
View in: PubMed

HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4.
View in: PubMed

The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006 Jun 15; 106(12):2576-82.
View in: PubMed

Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat. 2006 Dec; 100(3):301-8.
View in: PubMed

Acute lymphoblastic leukemia with 4;11 translocation analyzed by a multi-modal strategy of conventional cytogenetics, FISH, morphology, flow cytometry and molecular genetics, and review of the literature. Exp Mol Pathol. 2006 Aug; 81(1):62-71.
View in: PubMed

Cancer and leukemia group B breast committee: decades of progress and plans for the future. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3576s-80s.
View in: PubMed

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67.
View in: PubMed

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4 Suppl 1:S1-26.
View in: PubMed

Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s.
View in: PubMed

Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer. Womens Health (Lond). 2006 Jan; 2(1):89-97.
View in: PubMed

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006; 8(6):R66.
View in: PubMed

Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol. 2006 Jan 01; 24(1):85-94.
View in: PubMed

Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer. Med Image Comput Comput Assist Interv. 2006; 9(Pt 2):561-8.
View in: PubMed

Dose density in breast cancer: a simple message? J Natl Cancer Inst. 2005 Dec 07; 97(23):1712-4.
View in: PubMed

Standards for follow-up care of patents with breast cancer. Breast. 2005 Dec; 14(6):500-8.
View in: PubMed

Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8453-60.
View in: PubMed

Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
View in: PubMed

Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Res. 2005; 7(6):255-7.
View in: PubMed

Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504.
View in: PubMed

Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns. 2006 Oct; 63(1-2):104-9.
View in: PubMed

Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005 Oct 15; 104(8):1580-9.
View in: PubMed

American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20; 23(30):7703-20.
View in: PubMed

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov; 16(11):1772-7.
View in: PubMed

Ovarian suppression for breast cancer: an effective treatment in search of a home. J Clin Oncol. 2005 Sep 01; 23(25):5869-72.
View in: PubMed

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005 Aug 01; 23(22):5178-87.
View in: PubMed

Breast cancer. J Natl Compr Canc Netw. 2005 May; 3(3):238-89.
View in: PubMed

Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Res Treat. 2005 May; 91(2):153-61.
View in: PubMed

Fertility after breast cancer: questions abound. J Clin Oncol. 2005 Jul 01; 23(19):4259-61.
View in: PubMed

GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. Oncology (Williston Park). 2005 Apr; 19(4 Suppl 2):11-4.
View in: PubMed

Optimizing endocrine therapy for breast cancer. J Clin Oncol. 2005 Mar 10; 23(8):1609-10.
View in: PubMed

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005 Mar 02; 293(9):1073-81.
View in: PubMed

Offering participants results of a clinical trial: sharing results of a negative study. Lancet. 2005 Mar 12-18; 365(9463):963-4.
View in: PubMed

HER2 or not HER2: that is the question. J Clin Oncol. 2005 Jun 01; 23(16):3656-9.
View in: PubMed

Patient utilities for advanced cancer: effect of current health on values. Med Care. 2005 Feb; 43(2):173-81.
View in: PubMed

Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):348-57.
View in: PubMed

The association of ambulatory care with breast cancer stage at diagnosis among Medicare beneficiaries. J Gen Intern Med. 2005 Jan; 20(1):38-44.
View in: PubMed

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol. 2004 Dec; 31(6 Suppl 13):106-46.
View in: PubMed

Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2004 Dec; 31(6 Suppl 13):53-90.
View in: PubMed

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
View in: PubMed

Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004 Oct 15; 22(20):4174-83.
View in: PubMed

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 02; 351(10):971-7.
View in: PubMed

CNS metastases in breast cancer. J Clin Oncol. 2004 Sep 01; 22(17):3608-17.
View in: PubMed

New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004; 6(5):204-10.
View in: PubMed

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 01; 22(11):2061-8.
View in: PubMed

Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst. 2004 Apr 21; 96(8):629-32.
View in: PubMed

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004 Mar 01; 22(5):854-63.
View in: PubMed

Long-term complications of adjuvant chemotherapy for early stage breast cancer. Breast Dis. 2004; 21:55-64.
View in: PubMed

Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. J Clin Oncol. 2003 Dec 15; 21(24):4532-9.
View in: PubMed

Follow-up care of breast cancer survivors. Semin Oncol. 2003 Dec; 30(6):817-25.
View in: PubMed

Amifostine and chemoradiation therapy: ASCO responds. Lancet Oncol. 2003 Oct; 4(10):593.
View in: PubMed

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.
View in: PubMed

Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses. Psychooncology. 2003 Jul-Aug; 12(5):410-27.
View in: PubMed

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7.
View in: PubMed

Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7.
View in: PubMed

American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9.
View in: PubMed

Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003 Apr 15; 21(8):1447-51.
View in: PubMed

The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer. J Natl Compr Canc Netw. 2003 Apr; 1(2):215-21.
View in: PubMed

Do patients participating in clinical trials want to know study results? J Natl Cancer Inst. 2003 Mar 19; 95(6):491-2.
View in: PubMed

Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
View in: PubMed

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):1007-14.
View in: PubMed

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003 Feb 15; 21(4):602-6.
View in: PubMed

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9.
View in: PubMed

Clinical differences among the aromatase inhibitors. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):473S-9S.
View in: PubMed

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53.
View in: PubMed

Hormonal therapy in postmenopausal women with breast cancer. Oncology. 2003; 64(4):289-99.
View in: PubMed

Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S.
View in: PubMed

Complementary and alternative medicine use among women with breast cancer. J Clin Oncol. 2002 Sep 15; 20(18 Suppl):34S-8S.
View in: PubMed

Lumping versus splitting: the splitters take this round. J Clin Oncol. 2002 Sep 01; 20(17):3576-7.
View in: PubMed

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.
View in: PubMed

American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002 Aug 01; 20(15):3328-43.
View in: PubMed

Informing clinical trial participants about study results. JAMA. 2002 Jul 17; 288(3):363-5.
View in: PubMed

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002 Jun 15; 20(12):2895-903.
View in: PubMed

Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 11):38-43.
View in: PubMed

Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002 May 01; 94(9):652-61.
View in: PubMed

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Jan 01; 94(1):25-36.
View in: PubMed

Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test. 2002; 6(2):93-105.
View in: PubMed

Liposomal anthracyclines for breast cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 12):32-40.
View in: PubMed

New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58.
View in: PubMed

Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med. 2001 Jul-Aug; 10(6):589-98.
View in: PubMed

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001 Jun 01; 19(11):2875-82.
View in: PubMed

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in: PubMed

Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2001 May 01; 19(9):2381-9.
View in: PubMed

Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. Breast Dis. 2001; 14:41-50.
View in: PubMed

New combinations with Herceptin in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:50-7.
View in: PubMed

Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001; (30):135-42.
View in: PubMed

NCCN Practice Guidelines for Breast Cancer. Oncology (Williston Park). 2000 Nov; 14(11A):33-49.
View in: PubMed

Primary care for survivors of breast cancer. N Engl J Med. 2000 Oct 12; 343(15):1086-94.
View in: PubMed

Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years. Clin Breast Cancer. 2000 Jul; 1(2):164-5.
View in: PubMed

Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol. 2000 Jul; 18(14):2710-7.
View in: PubMed

Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2. J Genet Couns. 2000 Jun; 9(3):219-35.
View in: PubMed

Testing for hereditary breast and ovarian cancer in the southeastern United States. Ann Surg. 2000 May; 231(5):624-34.
View in: PubMed

Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
View in: PubMed

Involving family members in cancer care: focus group considerations of patients and oncological providers. Psychooncology. 2000 Mar-Apr; 9(2):101-12.
View in: PubMed

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer. 2000 Feb 15; 88(4):825-34.
View in: PubMed

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999 Oct; 17(10):3333-55.
View in: PubMed

Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6.
View in: PubMed

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999 Aug; 17(8):2506-13.
View in: PubMed

Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
View in: PubMed

Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol. 1999 May; 17(5):1465-73.
View in: PubMed

Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol. 1999 Apr; 10(4):397-402.
View in: PubMed

Assessing the cost-effectiveness of postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999 Apr 01; 44(1):91-8.
View in: PubMed

Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol. 1999 Mar; 17(3):1040-6.
View in: PubMed

Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psychooncology. 1999 Mar-Apr; 8(2):167-76.
View in: PubMed

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol. 1999 Jan; 17(1):52-63.
View in: PubMed

Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1999; 43(1):68-72.
View in: PubMed

Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer. 1998 Oct 01; 83(7):1362-8.
View in: PubMed

Oral 5-FU analogues in the treatment of breast cancer. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):39-43.
View in: PubMed

Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making. 1998 Oct-Dec; 18(4):365-75.
View in: PubMed

Overestimation of hereditary breast cancer risk. Ann Surg. 1998 Sep; 228(3):375-84.
View in: PubMed

An integrated genetic linkage map of the laboratory rat. Mamm Genome. 1998 Jul; 9(7):521-30.
View in: PubMed

Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25.
View in: PubMed

Cancer pain survey: patient-centered issues in control. J Pain Symptom Manage. 1998 May; 15(5):275-84.
View in: PubMed

Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol. 1998 Apr; 16(4):1380-7.
View in: PubMed

Informed consent for BRCA1 and BRCA2 testing. Breast Dis. 1998 Apr; 10(1-2):99-114.
View in: PubMed

Genetic testing for susceptibility to breast cancer: findings from women's focus groups. J Womens Health. 1997 Jun; 6(3):317-27.
View in: PubMed

Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr. 1997 May; 65(5):1495-501.
View in: PubMed

Weight gain in women diagnosed with breast cancer. J Am Diet Assoc. 1997 May; 97(5):519-26, 529; quiz 527-8.
View in: PubMed

A review of hereditary breast cancer: from screening to risk factor modification. Am J Med. 1997 Apr; 102(4):407-15.
View in: PubMed

Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997 Feb 05; 89(3):227-38.
View in: PubMed

Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemother Pharmacol. 1997; 40(4):335-41.
View in: PubMed

Factors contributing to patient satisfaction with breast reconstruction using silicone gel implants. Plast Reconstr Surg. 1996 Jun; 97(7):1420-6.
View in: PubMed

Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. J Infus Chemother. 1996; 6(4):211-6.
View in: PubMed

Cloning, characterization, and genetic mapping of the rat type 2 angiotensin II receptor gene. Hypertension. 1995 Dec; 26(6 Pt 1):998-1002.
View in: PubMed

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995 Oct; 13(10):2567-74.
View in: PubMed

Use of simple sequence length polymorphisms for genetic characterization of rat inbred strains. Mamm Genome. 1995 Sep; 6(9):595-601.
View in: PubMed

Predictability of heterozygosity scores and polymorphism information content values for rat genetic markers. Mamm Genome. 1995 Aug; 6(8):512-20.
View in: PubMed

Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Semin Oncol. 1995 Apr; 22(2 Suppl 5):72-8; discussion 78-9.
View in: PubMed

Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol. 1994 Sep; 12(9):1754-63.
View in: PubMed

Quality-of-life research in patients with breast cancer. Cancer. 1994 Jul 01; 74(1 Suppl):410-5.
View in: PubMed

Quality of life after bone marrow transplantation. Oncology (Williston Park). 1994 Jan; 8(1):19-27; discussion 27-8, 31.
View in: PubMed

Silicone controversy: a survey of women with breast cancer and silicone implants. J Natl Cancer Inst. 1993 Sep 01; 85(17):1407-11.
View in: PubMed

Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1993 Jul; 11(7):1418-29.
View in: PubMed

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun; 11(6):1132-43.
View in: PubMed

High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst. 1992 Dec 02; 84(23):1811-6.
View in: PubMed

Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Cancer Res. 1992 May 01; 52(9):2456-9.
View in: PubMed

Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys. 1990 Sep; 19(3):535-42.
View in: PubMed

The use of adjuvant chemotherapy for breast cancer in a community practice. Conn Med. 1985 May; 49(5):281-5.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top